Abstract:Objecitve To observe the correlation between serum C-reactive protein(CRP) level and chemotherapy efficacy in patients with advanced non-small cell lung cancer(NSCLC). Methods Sixty patients with advanced NSCLC received chemotherapy of gemcitabine/paclitaxel (GP) and gemcitabine/cisplatin (GC) regimes from January 2017 to August 2018 were enrolled.The serum CRP level was measured before and after each course of treatment; the imaging examinations were performed after every two treatment courses.According to response evaluation criteria in solid tumors (RECIST) criteria, the clinical effect was evaluated, and the correlation between CRP level and chemotherapy effect was observed. Results Single-factor analysis showed that the serum CRP level was not related to age, gender, smoking (all P>0.05), but was related to the score of Eastern Cancer Cooperation Group (ECOG), the size of the primary tumor and the different number of metastases (all P<0.05).In univariate survival analysis, serum CRP level, ECOG score, size of primary lesion and number of metastatic lesions were the important factors affecting the efficacy of chemotherapy.COX multivariate analysis showed that ECOG score, number of metastases and CRP level were the risk factors for the prognosis of NSCLC. Conclusion For advanced NSCLC patients, the presence of CRP is an independent adverse prognostic factor.The higher the CRP level, the worse the response to chemotherapy.